Loading viewer...
investor_presentation
Format: PDF investor_presentation
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs Copyright © 2021 Kintara Therapeutics, Inc. CONFIDENTIAL Corporate Presentation May 2021
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs
Copyright © 2021 Kintara Therapeutics, Inc. CONFIDENTIAL
Corporate Presentation
May 2021Forward Looking Statements
This presentation contains forward -looking statements based upon Kintara’s current expectations. This communication contains “fo rward -looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward -looking statements are identified by terminology such
as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “es timates,” “predicts,”
“potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. Kintara has based these
forward -looking statements largely on its then -current expectations and projections about future events, as well as the beliefs and assumptions of
management. Forward -looking statements are subject to a number of risks and uncertainties, many of which involve factors or circ umstances that are
beyond Kintara’s control, and actual results could differ materially from those stated or implied in forward -looking statements due to a number of
factors, including but not limited to: (i) risks associated with the impact of the COVID -19 pandemic; (ii) risks and uncertainties relating to Kintara’s
ability to develop, market and sell products based on its technology; the expected benefits and efficacy of Kintara’s product s and technology; the
availability of substantial additional funding for Kintara to continue its operations and to conduct research and development , clinical studies and
future product commercialization; and, Kintara’s business, research, product development, regulatory approval, marketing and dis tribution plans and
strategies (ii) whether the recently closed merger with Adgero Biopharmaceuticals will be successful, and (iii) those risks d etailed in Kintara’s most
recent Annual Report on Form 10- K and subsequent reports filed with the SEC, as well as other documents that may be filed by Kin tara from time to
time with the SEC. Accordingly, you should not rely upon forward -looking statements as predictions of future events. Kintara can not assure you that
the events and circumstances reflected in the forward -looking statements will be achieved or occur, and actual results could dif fer materially from
those projected in the forward -looking statements. The forward -looking statements made in this communication relate only to even ts as of the date
on which the statements are made. Except as required by applicable law or regulation, Kintara undertakes no obligation to upd ateany forward-looking
statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of un anticipated events.
Investors should not assume that any lack of update to a previously issued “forward -looking statement” constitutes a reaffirmation of that statement.
Preview truncated — download the full document for the complete content.
investor_presentation
22 Pages
investor_presentation
24 Pages
Alpine Income Property Trust
investor_presentation
VA Tech Wabag
Sonoma Pharmaceuticals Investor Presentation — November 2017
investor_presentationinvestor_presentation
11 Pages
Sonoma Pharmaceuticals, Inc.